Syros Pharmaceuticals,Inc. (NASDAQ:SYRS) Files An 8-K Entry into a Material Definitive Agreement

Syros Pharmaceuticals,Inc. (NASDAQ:SYRS) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Definitive Material Agreement.

Story continues below

On January8, 2019, Syros Pharmaceuticals,Inc., as tenant (the “Company”), and DIV 35 CPD, LLC, as landlord (the “Landlord”), entered into a Lease Agreement (the “Lease”) with respect to approximately 52,859 square feet of space in a building commonly known and numbered as 35 CambridgePark Drive in Cambridge, Massachusetts (the “Premises”).

The term of the Lease commences upon the Landlord’s delivery of the Premises to Company broom clean and free of all occupants, which is expected to occur on or about February1, 2019 (the “Commencement Date”) and shall continue until February28, 2030, unless earlier terminated in accordance with the terms of the Lease (the “Lease Term”). The Company has (i)the option to extend the Lease Term for one (1)additional ten (10)year period, and (ii)a right of first offer on space on the fifth floor and first floor of the building, consisting of 63,121 rentable square feet or less in the aggregate, subject to the terms and conditions of the Lease.

The initial fixed rental rate is $67.50 per rentable square foot of the Premises per annum, and will increase at a rate of three percent (3%) per year, with base rent first becoming due on March1, 2020. Under the terms of the Lease, the Landlord will provide an allowance in an amount not to exceed $9,514,620 (calculated at a rate of $180 per rentable square foot of the Premises) toward the cost of completing the initial buildout of the Premises. The Company will be required pay its share of operating expenses, taxes and any other expenses payable under the Lease.

The Lease is filed as Exhibit10.1 to this Current Report on Form8-K,and the above description of the Lease is qualified in its entirety by reference to such exhibit.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth above in Item 1.01 of this Current Report on Form8-Kregarding the Leaseis incorporated into this Item 2.03 by reference.

Item 9.01. Financial Statements and Exhibits.

Syros Pharmaceuticals, Inc. Exhibit
EX-10.1 2 a19-2322_1ex10d1.htm EX-10.1 Exhibit 10.1   Execution Copy   LEASE   between   DIV 35 CPD,…
To view the full exhibit click here

About Syros Pharmaceuticals,Inc. (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.

An ad to help with our costs